Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 4Phase 2/3 2Phase 1/2 2Phase 1 2Phase NA 1Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9Prostatic Neoplasms 5Neoplasms 5Multiple Myeloma 5Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Leiomyoma 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Hematologic Neoplasms 2Glioma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Vomiting 1Venous Thromboembolism 1Tuberous Sclerosis 1Thyroid Neoplasms 1Thyroid Diseases 1Thoracic Neoplasms 1Thalassemia 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pulmonary Embolism 1Primary Myelofibrosis 1Post-operative Seroma Formation 1Polycythemia Vera 1Pituitary Neoplasms 1Pelvic Pain 1

Interventions

rozanolixizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Myasthenia Gravis × 30 days × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡